Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 8/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 5/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429282 | 0.90 | GABRA5 (0.45) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL430191 | 0.83 | GABRA1 (0.44) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL427098 | 0.76 | GABRA5 (0.45) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL430677 | 0.70 | GABRG2 (0.51) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL26693931 | 0.70 | GABRA1 (0.47) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL26694278 | 0.68 | GABRA1 (0.45) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL23925953 | 0.68 | TSHR (0.46) | ALDH1A1KDM4EHIF1AMAPT | |
| SCHEMBL26694046 | 0.67 | GABRA5 (0.44) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL30781536 | 0.66 | GABRA1 (0.46) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL9527096 | 0.66 | EED (0.51) | GABRA5GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | GABRA5 61/4885GABRA1 19/4885GABRG2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.